Chu Benjamin F, Shana'ah Arwa, Hofmeister Craig C, Benson Don M, Sell Megan, Tucker Jill, Pichiorri Flavia, Efebera Yvonne A
Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, OH, United States.
Department of Pathology, Ohio State University, Columbus, OH, United States.
Eur J Case Rep Intern Med. 2014;1. doi: 10.12890/2014_000093.
Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and proangiogenic cytokines. The use of lenalidomide in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein with plasma cells, skin changes) has been reported, but its benefit in long-term use is not well established. A 55-year-old man with POEMS and debilitating polyneuropathy was treated with lenalidomide and dexamethasone followed by maintenance lenalidomide. He remains in haematologic remission and in complete recovery of functional status 3.5 years after diagnosis. This case supports the long-term use of lenalidomide in patients with POEMS syndrome.
来那度胺是一种治疗恶性浆细胞的有效疗法，也是一种对抗促炎和促血管生成细胞因子的强效药物。已有报道来那度胺用于POEMS综合征（多发性神经病变、脏器肿大、内分泌病、伴有浆细胞的单克隆蛋白、皮肤改变）的治疗，但长期使用的益处尚未明确。一名患有POEMS综合征和致残性多发性神经病变的55岁男性接受了来那度胺和地塞米松治疗，随后接受来那度胺维持治疗。诊断3.5年后，他仍处于血液学缓解状态，功能状态完全恢复。该病例支持在POEMS综合征患者中长期使用来那度胺。
